Pleiotropic effects of atorvastatin in rheumatoid arthritis patients with no history of cardiovascular diseases


Cite item

Full Text

Abstract

Aim. To evaluate the effect of atorvastatin (liprimar) on the laboratory values of inflammation and blood lipid composition in rheumatoid arthritis (RA) patients with no history of cardiovascular diseases (CVD). Subjects and methods. Fifty women with grade II RA activity according to DAS28 and radiologic (erosive) Stages I-III were examined; the patients were not former or current smokers; all were seropositive; their mean age was 50.2±9.9 years. All the patients with RA were divided into 2 groups: Group 1 took no atorvastatin and continued to receive standard previously prescribed therapy; Group 2 used atorvastatin in a dose of 20 mg. Lipidogram readings and the levels of Apo-A and Apo-B, neopterin, tumor necrosis factor-α, C-reactive protein, sP-selectin, sE-selectin, interleukin (IL)-6, IL-10, IL-12, and matrix metalloproteinases 3 and 9 were assessed. Results. The patients with RA show obvious blood lipid composition impairments. Incorporation of atorvastatin (liprimar) into combination therapy for RA not only causes a considerable reduction in total cholesterol, low-density lipoprotein cholesterol, triglycerides, and apo-B levels, but also positively affects the inflammatory activity of the disease, by lowering the level of proinflammatory cytokines and increasing that of the anti-inflammatory cytokine IL-10. Conclusion. The above changes may underlie the prevention of CVD complications in patients with RA.

References

  1. Попкова Т.В., Новикова Д.С., Насонов Е.Л. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: клинические рекомендации. M.: ГЭОТАР-Медиа; 2010:678-702.
  2. Peters MJ, Symmons DP, McCarey DW et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis — TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis. 2010;69(2):325-331.
  3. Van Halm VP, Peters MJ, Voskuyl AE et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: a cross-sectional study. Ann Rheum Dis. 2009;68:1395-1400.
  4. Maradit-Kremers H, Crowson CS, Therneau TM et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients. A population-based cohort study. Arthr Rheum. 2008;58(8):2268-2274.
  5. Goodson NI, Willes NJ, Lunt NC. Mortality on early inflamatory arthritis: cardiovascular mortality in seropositive patients. Arthr Rheum. 2002;46:2010-2019.
  6. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthr Rheum. 2005;35:8-17.
  7. Gerli R, Bartoloni Bocci E, Sherer Y et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:724-725.
  8. Lopez-Longo FJ, Oliver-Minarro D, de la Torre I et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthr Rheum. 2009;61:419-424.
  9. Meune C, Touze E, Trinqurte L et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analisis of cohort studies. Rheumatology. 2009;48(10):1309-1313.
  10. Gazi IF, Boumpas DT, Mikhailidis DP et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheum. 2007;25:102-111.
  11. Попкова Т.В., Новикова Д.С., Новиков А.А. и др. Роль нарушений в системе транспорта холестерина крови в развитии атеросклероза при ревматоидном артрите. Научно-практическая ревматология. 2007;5:4-10.
  12. Попкова Т.В., Новикова Д.С., Герасимова Е.В. и др. Значение факторов риска в прогнозировании клинических проявлений атеросклероза при СКВ и РА. Сб. матер. V съезда ревматологов России. М.; 2009:91.
  13. Bisoendial R, Stroes E, Kastelein J, Tak P. Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat Rev Rheum. 2010. doi: 10.1038/nrrheum.2009.277.
  14. Nurmohamed M, Dijkmans B. Dyslipidemia, statins and rheumatoid arthritis. Ann Rheum Dis. 2009;68:453-455.
  15. Nielen MJ, van Halm VP, Nurmohamed MT et al. Rheumatoid arthritis is preceded by a preclinical phase, characterized by increased C-reactive protein levels and a more atherogenic lipid profile. Arthr Rheum. 2003;48:344.
  16. Van Halm VP, Nielen MJ, Nurmohamed MT et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis. 2006;3:1-5.
  17. Myasoedova E, Gabriel S. Cardiovascular disease in rheumatoid arthritis: a step forward. Curr Opin Rheumatol. 2010;22:342-347.
  18. Bisoendial R, Stroes E, Kastelein J, Tak P. Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat Rev Rheum. 2010. doi: 10.1038/nrrheum.2009.277.
  19. Curtis J, John A, Baser O et al. Frequency of lipid testing in patients with rheumatoid arthritis: a retrospective database analysis. Arthr Rheum. 2009;60(Suppl. 10):s516.
  20. Toms TE, Panoulas VF, Douglas KM et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under treatment of lipid associated cardiovascular risk? Ann Rheum Dis. 2009;Oct 23 [Epub. ahead of print].
  21. Okamoto H, Koizumi K, Kamitsuji S et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol. 2007;34:964-968. http://www.cardiosite.ru.
  22. Шевченко О.П., Шевченко А.О. Статины. Ингибиторы ГМГ-КоА редуктазы. М.: Реафарм; 2002.
  23. Lindhardsen J, Ahlehoff O, Gislason G, Madsen OR, Olesen JB, Pedersen CT, Hansen PR. The risk of miocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danich nationwide cohort study. Ann Rheum Dis. 2011;70:929-934. doi: 10.1136/ard.2010.1433.
  24. Charles-Schoeman C, Khanna D, Furst DE et al. Effects of high-dose atorvastatin on anti-inflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: A pilot study. J Rheumatol. 2007;34(7):1458-1464.
  25. Дядык А.И., Багрий А.Э., Стуликова Е.Л. и др. Применение аторвастатина у больных ревматоидным артритом. Украинский ревматологический журнал. 2006;3(25):38-41.
  26. Lien LM, Hsieh YC. Association of blood active matrix metalloproteinase-3 with carotid plaque score from a community population in Taiwan. Atherosclerosis. 2010;212(2):595-600.
  27. Nissen SE, Tuzcu EM, Schoenhagen P et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-1080.
  28. Cannon CP, Braunwald E, Mc. Cabe CH et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:15-24.
  29. Khush KK, Waters D. Higher dose of potent statin better for high-risk patients. Cleveland Clin J Med. 2004;1:609-616.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies